About: PD-217,014

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.

Property Value
dbo:abstract
  • PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues. (en)
dbo:casNumber
  • 444088-20-4
dbo:fdaUniiCode
  • K2T93E812G
dbo:pubchem
  • 10313401
dbo:thumbnail
dbo:wikiPageID
  • 34542372 (xsd:integer)
dbo:wikiPageLength
  • 2164 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1082988024 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 10 (xsd:integer)
dbp:casNumber
  • 444088 (xsd:integer)
dbp:chemspiderid
  • 19264101 (xsd:integer)
dbp:h
  • 17 (xsd:integer)
dbp:iupacName
  • -3 (xsd:integer)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 10313401 (xsd:integer)
dbp:smiles
  • C1C[C@@H]2[C@H]1C[C@]CN (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NDDZVQRQVFTNSN-MBTKJCJQSA-N (en)
dbp:unii
  • K2T93E812G (en)
dbp:width
  • 175 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues. (en)
rdfs:label
  • PD-217,014 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License